Shares of Novavax, Inc. (NASDAQ:NVAX) ended Monday session at $2.08 with 11.27 million shares getting traded. Post opening the session at $2.09, the shares hit an intraday low of $2.06 and an intraday high of $2.17 and the price vacillated in this range throughout the day. The company has a market cap of $569.55 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company`s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email firstname.lastname@example.org or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company`s website for 90 days.
Shares of Eli Lilly and Co (NYSE:LLY) ended Monday session in green amid volatile trading. The shares closed up +0.74 points or 0.92% at $81.00 with 3.98 million shares getting traded. Post opening the session at $80.00, the shares hit an intraday low of $79.69 and an intraday high of $81.07 and the price vacillated in this range throughout the day. The company has a market cap of $89.99 billion and the numbers of outstanding shares have been calculated to be 1.10 billion shares.
Eli Lilly and Co (LLY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union (EU) with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and who have not been previously treated with doxorubicin. The CHMP reviewed olaratumab under EMA’s accelerated assessment program. If approved, olaratumab will be marketed under the trade name LARTRUVO™.
This is the first regulatory step in the world towards approval for olaratumab. The CHMP positive opinion is now referred for final action to the European Commission, which grants marketing authorization in the EU. The Commission usually makes a decision on marketing authorization within two to three months of the CHMP issuing its recommendation.
“Patients with advanced soft tissue sarcoma have been seeking new treatment options that can potentially extend lives, so they can have more time with their families and loved ones,” said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. “Advanced soft tissue sarcoma is a rare disease that is difficult to treat, and this milestone brings us one step closer to providing physicians in Europe with a new option that they can offer to their patients.”